JP7476183B2 - ラクトバチルス・プランタルムの組成物およびその使用 - Google Patents
ラクトバチルス・プランタルムの組成物およびその使用 Download PDFInfo
- Publication number
- JP7476183B2 JP7476183B2 JP2021520455A JP2021520455A JP7476183B2 JP 7476183 B2 JP7476183 B2 JP 7476183B2 JP 2021520455 A JP2021520455 A JP 2021520455A JP 2021520455 A JP2021520455 A JP 2021520455A JP 7476183 B2 JP7476183 B2 JP 7476183B2
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus plantarum
- dietary supplement
- pharmaceutical composition
- probiotic strain
- cfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 55
- 240000006024 Lactobacillus plantarum Species 0.000 title claims description 52
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims description 52
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims description 52
- 239000006041 probiotic Substances 0.000 claims description 79
- 230000000529 probiotic effect Effects 0.000 claims description 79
- 235000018291 probiotics Nutrition 0.000 claims description 79
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 49
- 102100032752 C-reactive protein Human genes 0.000 claims description 47
- 206010061218 Inflammation Diseases 0.000 claims description 46
- 230000004054 inflammatory process Effects 0.000 claims description 46
- 230000009885 systemic effect Effects 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 21
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 235000015872 dietary supplement Nutrition 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 15
- 241000282412 Homo Species 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 230000001332 colony forming effect Effects 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000021107 fermented food Nutrition 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 235000014058 juice drink Nutrition 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 11
- 230000009245 menopause Effects 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 229940069328 povidone Drugs 0.000 description 8
- 230000002550 fecal effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229920003109 sodium starch glycolate Polymers 0.000 description 5
- 239000008109 sodium starch glycolate Substances 0.000 description 5
- 229940079832 sodium starch glycolate Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 244000075850 Avena orientalis Species 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 235000021028 berry Nutrition 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000007963 capsule composition Substances 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100025255 Haptoglobin Human genes 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000015496 breakfast cereal Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000020415 coconut juice Nutrition 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000021001 fermented dairy product Nutrition 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000015141 kefir Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940080428 lactose 200 mg Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013384 milk substitute Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 108010027843 zonulin Proteins 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 244000172730 Rubus fruticosus Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000020197 coconut milk Nutrition 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 235000019226 kombucha tea Nutrition 0.000 description 1
- 235000020129 lassi Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000021135 plant-based food Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013548 tempeh Nutrition 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pediatric Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
「全身性炎症」とは、全身性炎症の意味を含む。これは一般に、免疫関連細胞からの炎症誘発性サイトカインの放出と自然免疫系の活性化の結果である。特に、慢性全身性炎症の意味を含む。これは通常、自然免疫系の活性化が初期の急性期を超えて持続し、「慢性」になる場合である。
「治療および/または予防における使用」とは、病気または状態に関連する1つ以上の症状および/または他のマーカーの予防、遅延、それからの保護、重症度の軽減および/または除去の対象において効果をもたらす使用の意味を含む。
C反応性タンパク質(CRP)は、肝臓で産生される急性期タンパク質であり、マクロファージおよびT細胞によるインターロイキン6の分泌に続いて増加する。したがって、血漿中のCRPのレベルは、体内の炎症の存在に応じて上昇する。CRPの生理学的役割は、C1qを介して補体系を活性化するために、死んだ細胞または死にかけている細胞(および一部の種類の細菌)の表面に発現するリゾホスファチジルコリンに結合することである。
プロバイオティクス細菌は、「適切な量で投与されると、宿主に健康上の利益をもたらす生きた微生物」として定義される(Hill et al,Nat Rev Gastroenterol Hepatol,2014,11(8):506-514)。ラクトバチルス属およびビフィズス菌属の細菌は、プロバイオティクス製品で最も頻繁に使用される細菌である。これらの細菌は、これらの有機体に基づくプロバイオティクス製品と同様に、一般的に安全である。細菌がプロバイオティクスの定義を満たすためには、通常、腸内で生き残り、腸にコロニーを形成し、生産と貯蔵のプロセスを生き残り、消費者の健康にプラスの効果があるという証拠を持っている必要がある。
本発明の第1の態様によるラクトバチルス・プランタルムの少なくとも1つのプロバイオティクス株は、ヒトでの使用に好適でなければならない。例えば、ヒトは、40、45、50、55、60、65、70、75、80、85、または90歳を超える可能性がある。
本発明の第1の態様による少なくとも1つのプロバイオティクス株は、少なくとも1つの好適な担体を含む組成物中に存在し得る。例えば、担体は、希釈剤または賦形剤であり得る。組成物は、固体または液体製剤としてのものであり得、したがって、少なくとも1つの担体は、固体または液体であり得、または少なくとも1つの固体成分および少なくとも1つの液体成分の両方を含み得る。
本発明の第2の態様は、ヒトにおける加齢性全身性炎症の治療および/または予防に使用するための、本発明の第1の態様による少なくとも1つのプロバイオティクス株、および1つ以上の薬学的に許容される賦形剤を含む薬学的組成物を提供する。
本発明の第3の態様は、ヒトにおける加齢性全身性炎症を治療および/または予防するための方法であって、それを必要とするヒトに、本発明の第1の態様による治療上有効量の少なくとも1つのプロバイオティクス株または本発明の第2の態様による薬学的組成物を投与することを含む、方法を提供する。
本発明の第4の態様は、ヒトにおける加齢性全身性炎症の治療および/または予防における、本発明の第1の態様による少なくとも1つのプロバイオティクス株を含む組成物、または本発明の第2の態様による薬学的組成物の使用を提供する。
上記で参照された(および参照により本明細書に組み込まれる)製剤に加えて、以下の実施例は、本発明による薬学的製剤を例示する。
実施例A:錠剤
プロバイオティクス菌株(複数可) 1×109CFU
乳糖 200mg
デンプン 50mg
ポリビニルピロリドン 5mg
ステアリン酸マグネシウム 4mg
以下の製剤AおよびBは、ポビドンの溶液での成分の湿式造粒、続いてステアリン酸マグネシウムの添加および圧縮によって調製される。
製剤A
(a)プロバイオティクス株(複数可) 1×109CFU 1×109CFU
(b)乳糖血圧 210mg 26mg
(c)ポビドンB.P. 15m 9mg
(d)デンプングリコール酸ナトリウム 20mg 12mg
(e)ステアリン酸マグネシウム 5mg 3mg
製剤B
(a)プロバイオティクス株(複数可) 1×109CFU 1×109CFU
(b)乳糖 150mg
(c)アビセルPH 101(登録商標) 60mg 26mg
(d)ポビドンB.P. 15mg 9mg
(e)デンプングリコール酸ナトリウム 20mg 12mg
(f)ステアリン酸マグネシウム 5mg 3mg
製剤C
プロバイオティクス菌株(複数可) 1×109CFU
乳糖 200mg
デンプン 50mg
ポビドン 5mg
ステアリン酸マグネシウム 4mg
製剤D
プロバイオティクス菌株(複数可) 1×109CFU
アルファ化デンプンNF15 150mg
製剤E
プロバイオティクス菌株(複数可) 1×109CFU
乳糖 150mg
アビセル(登録商標) 100mg
製剤Aは、ポビドンの溶液での成分(以下)の湿式造粒、続いてステアリン酸マグネシウムの添加および圧縮によって調製される。
(a)プロバイオティクス株(複数可) 1x109CFU
(b)ヒドロキシプロピルメチルセルロース 112mg
(Methocel K4M Premium)(登録商標)
(c)ラクトースB.P. 53mg
(d)ポビドンB.P.C. 28mg
(e)ステアリン酸マグネシウム 7mg
製剤A
カプセル製剤は、上記の実施例Bにおける製剤Dの成分を混合し、2パート硬質ゼラチンカプセルに充填することによって調製される。製剤B(下記)は、同様の方法で調製される。
製剤B
(a)プロバイオティクス株(複数可) 1×109CFU
(b)乳糖血圧 143mg
(c)デンプングリコール酸ナトリウム 25mg
(d)ステアリン酸マグネシウム 2mg
製剤C
(a)プロバイオティクス株 1×109CFU
(b)マクロゴール4000BP 350mg
以下の制御放出カプセル製剤は、押出機を使用して成分a、b、およびcを押し出し、続いて押出物を球状化し、乾燥させることによって調製される。次いで、乾燥ペレットを放出制御膜(d)でコーティングし、2ピース硬質ゼラチンカプセルに充填する。
(a)プロバイオティクス株 1×109CFU
(b)微結晶性セルロース 125mg
(c)ラクトースBP 125mg
(d)エチルセルロース 13mg
材料および方法
プロバイオティクス製品の抗炎症活性の可能性は、低度の全身性炎症(C反応性タンパク質で定義、血清レベル2~10mg/L)の70歳を超える66人の健康な参加者を対象としたランダム化二重盲検プラセボ対照試験で評価された。
・研究に含める前の過去4週間の抗生物質治療の摂取。
・現在、コルチコステロイド治療中。
・慢性炎症性疾患の存在。
1.ラクトバチルス・プランタルムHeal9(Lp Heal9)
2.ラクトバチルス・プランタルムHeal9+ベリー(Bar+Lp Heal9)
3.プラセボ
1.糞便試料は、カルプロテクチン(腸の炎症のマーカー)およびゾヌリン(腸壁の細胞間の密着結合の透過性を調節し、腸の透過性の増加のマーカーとして使用されるタンパク質)の分析に使用された。
2.全身性炎症マーカーCRPおよびフィブリノーゲンの分析には血液試料を使用した。
ウィルコクソン順位和検定は、研究の統計分析に使用された。
CRPとカルプロテクチンで得られた結果は、ラクトバチルス・プランタルム、特にラクトバチルス・プランタルムHEAL9が、健康な高齢者の加齢性全身性炎症の治療および/または予防に有効であることを示している。
Claims (19)
- ヒトにおける加齢性全身性炎症を治療および/または予防するための薬学的組成物であって、
(a)ラクトバチルス・プランタルムHEAL9(DSM15312);および
(b)1つ以上の、薬学的に許容される担体または薬学的に許容される賦形剤
を含む、薬学的組成物。 - 前記ヒトが、60、65、70、75、80、85、または90歳を超えた年齢である、請求項1に記載の薬学的組成物。
- 前記ヒトが、2~10mg/Lまたは3~10m/Lの血清C反応性タンパク質(CRP)レベルによって示される全身性炎症を有する、請求項1または2に記載の薬学的組成物。
- 前記薬学的組成物中のラクトバチルス・プランタルムの前記少なくとも1つのプロバイオティクス株が、用量当たり約106~約1014コロニー形成単位(CFU)である、請求項1~3のいずれか1項に記載の薬学的組成物。
- 前記薬学的組成物中のラクトバチルス・プランタルムの前記少なくとも1つのプロバイオティクス株が、用量当たり約109~約1011CFUである、請求項4に記載の薬学的組成物。
- 前記薬学的組成物は、1日当たり1回以上の用量で投与され、前記組成物中のラクトバチルス・プランタルムの前記少なくとも1つのプロバイオティクス株の前記1日用量が、1日当たり約106~約1014CFUである、請求項1~5のいずれか1項に記載の薬学的組成物。
- 加齢性全身性炎症の前記治療および/または予防が、C反応性タンパク質(CRP)のレベルの増加を低減および/もしくは抑制すること、ならびに/またはカルプロテクチンのレベルの増加を低減および/もしくは抑制することを含む、請求項1~6のいずれか1項に記載の薬学的組成物。
- 前記組成物が、溶液、懸濁液、乳濁液、錠剤、顆粒、粉末、カプセル、トローチ、チューインガム、または坐剤の形態で提供される、請求項1~7のいずれか1項に記載の薬学的組成物。
- ヒトにおける加齢性全身性炎症を治療および/または予防するための栄養補助商品であって、
(a)ラクトバチルス・プランタルムHEAL9(DSM15312);および
(b)1つ以上の担体
を含む、栄養補助食品。 - 前記ヒトが、60、65、70、75、80、85、または90歳を超えた年齢である、請求項9に記載の栄養補助食品。
- 前記ヒトが、2~10mg/Lまたは3~10m/Lの血清C反応性タンパク質(CRP)レベルによって示される全身性炎症を有する、請求項9または10に記載の栄養補助食品。
- 前記栄養補助食品中のラクトバチルス・プランタルムの前記少なくとも1つのプロバイオティクス株が、用量当たり約106~約1014コロニー形成単位(CFU)である、請求項9~11のいずれか1項に記載の栄養補助食品。
- 前記組成物中のラクトバチルス・プランタルムの前記少なくとも1つのプロバイオティクス株が、用量当たり約109~約1011CFUである、請求項12に記載の栄養補助食品。
- 前記栄養補助食品は、1日当たり1回以上の用量で投与され、前記栄養補助食品中のラクトバチルス・プランタルムの前記少なくとも1つのプロバイオティクス株の前記1日用量が、1日当たり約106~約1014CFUである、請求項9~13のいずれか1項に記載の栄養補助食品。
- 加齢性全身性炎症の前記治療および/または予防が、C反応性タンパク質(CRP)のレベルの増加を低減および/もしくは抑制すること、ならびに/またはカルプロテクチンのレベルの増加を低減および/もしくは抑制することを含む、請求項9~14のいずれか1項に記載の栄養補助食品。
- 前記栄養補助食品が、溶液、懸濁液、乳濁液、錠剤、顆粒、粉末、カプセル、トローチ、チューインガム、または坐剤の形態で提供される、請求項9~15のいずれか1項に記載の栄養補助食品。
- ヒトにおける加齢性全身性炎症を治療および/または予防するための食品組成物であって、
(a)ラクトバチルス・プランタルムHEAL9(DSM15312);および
(b)食品
を含む、食品組成物。 - 前記食品が、穀物ベースの製品、乳製品、ジュース飲料、または発酵食品である、請求項17に記載の食品組成物。
- 前記食品組成物中のラクトバチルス・プランタルムの前記少なくとも1つのプロバイオティクス株が、用量当たり約106~約1014コロニー形成単位(CFU)である、請求項17または18に記載の食品組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2018/066154 WO2019242839A1 (en) | 2018-06-18 | 2018-06-18 | Lactobacillus plantarum compositions and uses thereof |
EPPCT/EP2018/066154 | 2018-06-18 | ||
PCT/EP2019/065590 WO2019243169A1 (en) | 2018-06-18 | 2019-06-13 | Lactobacillus plantarum compositions and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021527718A JP2021527718A (ja) | 2021-10-14 |
JPWO2019243169A5 JPWO2019243169A5 (ja) | 2022-05-17 |
JP7476183B2 true JP7476183B2 (ja) | 2024-04-30 |
Family
ID=62842054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021520455A Active JP7476183B2 (ja) | 2018-06-18 | 2019-06-13 | ラクトバチルス・プランタルムの組成物およびその使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210154248A1 (ja) |
EP (1) | EP3806876B1 (ja) |
JP (1) | JP7476183B2 (ja) |
KR (1) | KR20210023972A (ja) |
CN (1) | CN112638393A (ja) |
AU (1) | AU2018428571A1 (ja) |
BR (1) | BR112020026076A2 (ja) |
CA (1) | CA3102445A1 (ja) |
ES (1) | ES2966935T3 (ja) |
MX (1) | MX2020013860A (ja) |
PL (1) | PL3806876T3 (ja) |
WO (2) | WO2019242839A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009511471A (ja) | 2005-10-06 | 2009-03-19 | プロビ エービー | 自己免疫疾患治療のための乳酸菌の使用 |
WO2017125446A1 (en) | 2016-01-19 | 2017-07-27 | Probi Ab | Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070098784A1 (en) | 2001-09-28 | 2007-05-03 | Nutraceutix, Inc. | Delivery system for biological component |
JP5041651B2 (ja) | 2001-09-28 | 2012-10-03 | ティーエヌティーギャンブル・インコーポレーテッド | 生物体成分の送達系 |
SE527555C2 (sv) * | 2003-04-04 | 2006-04-11 | Probi Ab | Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar |
CN101325960B (zh) * | 2005-10-06 | 2012-05-30 | 普罗比公司 | 乳酸杆菌用于治疗自身免疫性疾病的用途 |
SE532899C2 (sv) * | 2007-06-08 | 2010-05-04 | Probi Ab | Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel |
SE533778C2 (sv) * | 2009-05-14 | 2011-01-11 | Probi Ab | Probiotisk fruktdryck |
CA2951739C (en) | 2014-07-01 | 2023-09-19 | Tntgamble, Inc. | Bi-layer dual release probiotic tablets |
WO2017060477A1 (en) | 2015-10-07 | 2017-04-13 | Bifodan A/S | Probiotic formulation |
-
2018
- 2018-06-18 AU AU2018428571A patent/AU2018428571A1/en active Pending
- 2018-06-18 CA CA3102445A patent/CA3102445A1/en active Pending
- 2018-06-18 WO PCT/EP2018/066154 patent/WO2019242839A1/en active Application Filing
- 2018-06-18 KR KR1020217000189A patent/KR20210023972A/ko not_active Application Discontinuation
-
2019
- 2019-06-13 JP JP2021520455A patent/JP7476183B2/ja active Active
- 2019-06-13 MX MX2020013860A patent/MX2020013860A/es unknown
- 2019-06-13 PL PL19733414.7T patent/PL3806876T3/pl unknown
- 2019-06-13 EP EP19733414.7A patent/EP3806876B1/en active Active
- 2019-06-13 ES ES19733414T patent/ES2966935T3/es active Active
- 2019-06-13 WO PCT/EP2019/065590 patent/WO2019243169A1/en unknown
- 2019-06-13 BR BR112020026076-2A patent/BR112020026076A2/pt unknown
- 2019-06-13 CN CN201980040689.1A patent/CN112638393A/zh active Pending
- 2019-06-13 US US17/252,854 patent/US20210154248A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009511471A (ja) | 2005-10-06 | 2009-03-19 | プロビ エービー | 自己免疫疾患治療のための乳酸菌の使用 |
WO2017125446A1 (en) | 2016-01-19 | 2017-07-27 | Probi Ab | Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation |
Non-Patent Citations (2)
Title |
---|
European Journal of Nutrition,2014年11月19日,Vol. 54,p.1161-1171,doi: 10.1007/s00394-014-0794-9 |
Orally administrated Lactobacillus pentosus var. plantarum C29 ameliorates age-dependent colitis by inhibiting the nuclear factor-kappa B signaling pathway via the regulation of lipopolysaccharide production by gut microbiota,PLoS One,2015年02月17日,doi: 10.1371/journal.pone.0116533. eCollection 2015. |
Also Published As
Publication number | Publication date |
---|---|
WO2019242839A1 (en) | 2019-12-26 |
US20210154248A1 (en) | 2021-05-27 |
JP2021527718A (ja) | 2021-10-14 |
CN112638393A (zh) | 2021-04-09 |
EP3806876C0 (en) | 2023-09-20 |
KR20210023972A (ko) | 2021-03-04 |
WO2019243169A1 (en) | 2019-12-26 |
MX2020013860A (es) | 2021-03-25 |
EP3806876A1 (en) | 2021-04-21 |
AU2018428571A1 (en) | 2021-01-28 |
EP3806876B1 (en) | 2023-09-20 |
CA3102445A1 (en) | 2019-12-26 |
PL3806876T3 (pl) | 2024-03-25 |
BR112020026076A2 (pt) | 2021-03-23 |
ES2966935T3 (es) | 2024-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2837479C (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
US20200121740A1 (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
Kullen et al. | The delivery of probiotics and prebiotics to infants | |
BRPI0616962A2 (pt) | uso de lactobacillus para o tratamento de doenças autoimunes | |
JP7434375B2 (ja) | 腸管免疫調節のための新規なプロバイオティック組成物 | |
Faujdar et al. | Role of probiotics in human health and disease: an update | |
JP5816273B2 (ja) | 経上皮抵抗の改善に用いるためのプロバイオティクス株 | |
JP2003306436A (ja) | 血清コレステロール上昇抑制剤 | |
JP7476183B2 (ja) | ラクトバチルス・プランタルムの組成物およびその使用 | |
RU2773847C1 (ru) | Композиции lactobacillus plantarum и их применение | |
Sudha et al. | Effect of capsule'UB03'containing potential probiotic strains for the treatment of patients with irritable bowel syndrome | |
JP2010132580A (ja) | 脂質代謝改善効果を有する乳酸菌 | |
JP7257665B2 (ja) | 経口組成物 | |
WO2022244447A1 (ja) | 破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨代謝改善用組成物 | |
US20220313758A1 (en) | Lactobacillus compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220509 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230228 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231205 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240409 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240417 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7476183 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |